Polifarma

SIFI and Polifarma announce licensing agreement to market ophthalmology product portfolio in Italy

SIFI and Polifarma S.p.A. announce the conclusion of an agreement to license sales in Italy for Carteol, Colbiocin ointment, Epinerve, Genticol, Pensulvit, Lubristil and Mirtilene Forte.

 

Catania, November 22, 2016 - SIFI, the Italian leading ophthalmic company, and Polifarma S.p.A., a long standing Italian pharmaceutical, announce the conclusion of an agreement to license sales in Italy for Carteol, Colbiocin ointment, Epinerve, Genticol, Pensulvit, Lubristil and Mirtilene Forte.

Developed by SIFI during its extensive history, these products boast a proven effectiveness in the treatment of important illnesses, such as glaucoma and dry eye and in treating ocular infections.

According to the agreement terms, Polifarma will be in charge of all activities relating to scientific information, distribution and sales of the above mentioned products on the Italian territory, whereas SIFI will continue to deal with production and regulatory compliance.

"After careful evaluation, SIFI has decided to entrust a variety of products, which have contributed in writing its history, to a company that shares the same values of integrity and service to the medical community", declared Fabrizio Chines, SIFI President and CEO. "We are persuaded that Polifarma, a company that intends to penetrate the ophthalmology industry thanks to the partnership with SIFI, will assure the development of these products, through a widespread scientific information, highlighting the added value for patients".

"Our company, has in its DNA the capacity to perceive project potential, so it seized the opportunity SIFI offered, through this agreement to enter the ophthalmology area, previously not represented in our portfolio" declared Andrea Bracci, Polifarma CEO. "We are sure of the validity of the products, the investments supporting these and the quality of our organization, which will allow to relaunch the brands that have been entrusted to us.

SIFI

SIFI is the leading Italian ophthalmic company, focused on eye care since 1935. SIFI designs, manufactures and markets innovative pharmaceutical specialty products, surgical and medical devices. Headquartered in Catania, Sicily, SIFI operates directly in Italy, Romania and Mexico with a staff of more than 350 people worldwide. Since June 2015, SIFI is backed by 21 Investimenti, a private equity firm founded by Alessandro Benetton, which supports the company’s international expansion and portfolio development strategy. More information available at www.sifigroup.com.

POLIFARMA

Founded in Italy in 1919, Polifarma is now part of the Final Spa, a Financial Group owned by Mrs Luisa Angelini. The company is active in Cardiovascular, Gastroenterology, Central Nervous System and Infectious Diseases areas. With a capillary network of selected ISF in two distinct lines, Polifarma represents a reference point for the medical class from years. The company’s philosophy is characterised by values that start with personal attention, focussing on results, dynamism and innovation and an ever attentive eye on the national and international market. More information available at www.polifarma.it.


More information available at:
Communication Office SIFI SpA c/o CITYnet - Roma
mailto:press@sifigroup.com +39 3336999669

Share
 
Polifarma

Polifarma SpA - Share Capital €1,000,000.00 - fully paid up Comp. Register Rome - Tax Code 00403210586 - Economic Index (REA) Rome No. 11913 - VAT No. 00882341001